Cite
Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC– Ain’t no mountain high enough…. to keep me getting to you.
MLA
Jeremic, Branislav, et al. “Low Level Evidence Supporting the Choice of Optimal Multimodality Treatment Approach in Patients with Stage IIIA NSCLC– Ain’t No Mountain High Enough…. to Keep Me Getting to You.” Lung Cancer (01695002), vol. 123, Sept. 2018, pp. 172–73. EBSCOhost, https://doi.org/10.1016/j.lungcan.2018.06.016.
APA
Jeremic, B., Gomez-Caamano, A., Dubinsky, P., Cihoric, N., Igrutinovic, I., & Videtic, G. (2018). Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC– Ain’t no mountain high enough…. to keep me getting to you. Lung Cancer (01695002), 123, 172–173. https://doi.org/10.1016/j.lungcan.2018.06.016
Chicago
Jeremic, Branislav, Antonio Gomez-Caamano, Pavol Dubinsky, Nikola Cihoric, Ivan Igrutinovic, and Gregory Videtic. 2018. “Low Level Evidence Supporting the Choice of Optimal Multimodality Treatment Approach in Patients with Stage IIIA NSCLC– Ain’t No Mountain High Enough…. to Keep Me Getting to You.” Lung Cancer (01695002) 123 (September): 172–73. doi:10.1016/j.lungcan.2018.06.016.